Incorporating Patient Preferences of Older Adults in Oncology Trials
Incorporating Patient Preferences of Older Adults in Oncology Trials oncologynurseadvisor.com
Онкология
🎗️Лента новостей
Онкология
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer BioSpace
Онкология
Решение для поддержки лечения рака с использованием имбиря.
Решение для поддержки лечения рака с использованием имбиря. Vietnam.vn
Онкология
AstraZeneca's Phase 3 Trial of Combination Treatment for Breast Cancer Fails to Meet Primary Endpoint
AstraZeneca's Phase 3 Trial of Combination Treatment for Breast Cancer Fails to Meet Primary Endpoint marketscreener.com
🎗️
Онкология
Telix Pharma получила одобрение FDA для лечения рака мозга
Telix Pharma получила одобрение FDA для лечения рака мозга Investing.com
Онкология
Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR lung cancer
Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented at the International Association for the Study…
Онкология
First-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant lung cancer
First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to primary results from the phase 3 DESTINY-Lung04…
Онкология
Update shows sustained overall survival benefit with adjuvant osimertinib in resected EGFR-mutated lung cancer
An exploratory 8-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB–IIIA non-small cell lung cancer (NSCLC). The findings were presented at the International…
Онкология
Zidesamtinib demonstrates 93% response rate in ROS1-positive lung cancer
New results from the global phase 1/2 ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI). The findings were presented at the International…
Онкология
Amivantamab-chemotherapy demonstrates longest overall survival reported for lung cancer with EGFR mutation
Results from the phase 3 PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) was associated with numerically longer overall survival compared with chemotherapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC) with EGFR exon 20…
Онкология
79% were alive eight years later on AstraZeneca's lung-cancer drug, versus 64% on placebo.
79% were alive eight years later on AstraZeneca's lung-cancer drug, versus 64% on placebo. Stock Titan
🎗️
Онкология
Немедленно выбросьте это из холодильника! Какие продукты могут спровоцировать развитие рака: мнения врачей
Немедленно выбросьте это из холодильника! Какие продукты могут спровоцировать развитие рака: мнения врачей Дзен
Онкология
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer Investing News Network
🎗️
Онкология
Опасность в каждом кусочке: какие продукты повышают риск развития рака
Опасность в каждом кусочке: какие продукты повышают риск развития рака news.ru
Онкология
New analysis points to low overdiagnosis in breast cancer screening
When women take part in breast cancer screening, they are informed that screening may detect cancers that would never have caused symptoms or problems during their lifetime. This is known as overdiagnosis.